PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+30.71%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.66B
AUM Growth
+$4.66B
(+12%)
Cap. Flow
-$219M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
123
New
13
Increased
23
Reduced
25
Closed
18
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$112M |
| 2 |
Viking Therapeutics
VKTX
|
$62M |
| 3 |
argenx
ARGX
|
$56M |
| 4 |
Nuvalent
NUVL
|
$44M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$37.6M |
Top Sells
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$50.4M |
| 4 |
Natera
NTRA
|
$39.4M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$38.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Instil Bio
TIL
$182M
| $23.3M | 0.49% | +345,545 | New | +$23.3M |
|
52
LivaNova
LIVN
$3.08B
| $22.5M | 0.48% | 429,000 -15,000 | -3% | -$788K |
|
|
SWTX
53
DELISTED
SpringWorks Therapeutics
SWTX
| $22.2M | 0.47% | 692,263 -960,699 | -58% | -$30.8M |
|
54
Medtronic
MDT
$119B
| $22.1M | 0.47% | 245,332 -245,333 | -50% | -$22.1M |
|
55
ADMA Biologics
ADMA
$4.12B
| $21.2M | 0.45% | 1,060,200 -1,710,800 | -62% | -$34.2M |
|
56
Xenon Pharmaceuticals
XENE
$2.98B
| $20.7M | 0.44% | 524,930 -58,326 | -10% | -$2.3M |
|
|
ZBIO
57
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $19.4M | 0.41% | +1,144,035 | New | +$19.4M |
|
58
Disc Medicine
IRON
$2.07B
| $19M | 0.4% | 387,017 -166,420 | -30% | -$8.18M |
|
59
Rocket Pharmaceuticals
RCKT
$354M
| $17.2M | 0.36% | 931,851 -314,746 | -25% | -$5.81M |
|
60
Inhibrx
INBX
$408M
| $16.7M | 0.35% | 1,064,026 | – | – |
|
|
RAPP
61
Rapport Therapeutics
RAPP
$643M
| $15.3M | 0.32% | 748,183 | – | – |
|
62
Merus
MRUS
$4.98B
| $15M | 0.32% | 300,000 | – | – |
|
63
Insmed
INSM
$28.8B
| $13.1M | 0.28% | 180,000 | – | – |
|
64
Icon
ICLR
$13.8B
| $12.7M | 0.27% | 44,353 +13,103 | +42% | +$3.76M |
|
65
Arcutis Biotherapeutics
ARQT
$1.86B
| $12.6M | 0.27% | 1,358,500 -200,000 | -13% | -$1.86M |
|
66
PepGen
PEPG
$38M
| $12.1M | 0.26% | 1,410,438 | – | – |
|
67
Tyra Biosciences
TYRA
$675M
| $12M | 0.25% | 511,226 -496,141 | -49% | -$11.7M |
|
68
Xencor
XNCR
$580M
| $10.6M | 0.22% | +527,671 | New | +$10.6M |
|
69
Verrica Pharmaceuticals
VRCA
$52.8M
| $10.3M | 0.22% | 7,099,182 | – | – |
|
70
Roivant Sciences
ROIV
$8.15B
| $9.78M | 0.21% | +847,745 | New | +$9.78M |
|
71
ArriVent BioPharma
AVBP
$776M
| $9.75M | 0.21% | 415,000 | – | – |
|
72
Exact Sciences
EXAS
$8.98B
| $8.52M | 0.18% | +125,000 | New | +$8.52M |
|
73
EyePoint Pharmaceuticals
EYPT
$797M
| $8.29M | 0.18% | 1,037,274 +397,000 | +62% | +$3.17M |
|
74
Allogene Therapeutics
ALLO
$251M
| $7.63M | 0.16% | 2,725,000 | – | – |
|
75
Amylyx Pharmaceuticals
AMLX
$836M
| $6.89M | 0.15% | +2,125,649 | New | +$6.89M |
|